Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

07:37
10/06/16
10/06
07:37
10/06/16
07:37

Alnylam news not a negative read through on other RNAi drugs, says RBC Capital

After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ARWR

Arrowhead

$7.52

0.23 (3.16%)

ABUS

Arbutus Biopharma

$3.50

0.125 (3.71%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
JEFF
10/06/16
NO CHANGE
Target $58
JEFF
Buy
Alnylam price target lowered to $58 from $86 at Jefferies
Jefferies analyst Gena Wang lowered her price target for Alnylam Pharmaceuticals to $58 from $86 following the termination of revusiran Phase 3 due to mortality imbalance. The analyst believes the setback, while "major," is likely to be program specific and not impact the company's other trials. She keeps a Buy rating on Alnylam.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
ARWR Arrowhead
$7.52

0.23 (3.16%)

08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
08/17/16
CANT
08/17/16
INITIATION
Target $15
CANT
Buy
Arrowhead initiated with a Buy at Cantor
Target $15.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
ABUS Arbutus Biopharma
$3.50

0.125 (3.71%)

08/19/16
08/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aratana Therapeutics (PETX) assumed with a Buy at Jefferies. 2. Arbutus Biopharma (ABUS) initiated with an Outperform at William Blair. 3. Acceleron (XLRN) initiated with a Buy at BTIG. 4. Agios Pharmaceuticals (AGIO) initiated with a Neutral at BTIG. 5. Suncor (SU) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $7
WBLR
Outperform
Arbutus Biopharma initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arbutus Biopharma with an Outperform rating and $7 price target.
08/05/16
LEER
08/05/16
DOWNGRADE
LEER
Market Perform
Arbutus Biopharma downgraded to Market Perform from Outperform at Leerink
07/08/16
CHDN
07/08/16
DOWNGRADE
CHDN
Sell
Arbutus Biopharma downgraded to Sell from Neutral at Chardan

TODAY'S FREE FLY STORIES

ICHR

Ichor Holdings

$25.60

0.86 (3.48%)

08:04
01/17/18
01/17
08:04
01/17/18
08:04
Earnings
Ichor Holdings sees Q4 revenue $183M, consensus $181.17M »

Ichor Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

RGC

Regal Entertainment

$22.90

-0.07 (-0.30%)

08:03
01/17/18
01/17
08:03
01/17/18
08:03
Downgrade
Regal Entertainment rating change  »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.55 (-2.93%)

08:03
01/17/18
01/17
08:03
01/17/18
08:03
Hot Stocks
GE Transportation signs locomotive, service agreements valued at over $900M »

GE Transportation signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DWDP

DowDuPont

$74.95

-0.46 (-0.61%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
DowDuPont, UC Davis team up to advance orphan African crops »

Dow AgroSciences teamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

NTN

NTN Buzztime

$4.91

0.3 (6.51%)

, BWLD

Buffalo Wild Wings

$156.65

-0.1 (-0.06%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
NTN Buzztime digital menu and payment go live at Buffalo Wild Wings »

NTN Buzztime (NTN), has…

NTN

NTN Buzztime

$4.91

0.3 (6.51%)

BWLD

Buffalo Wild Wings

$156.65

-0.1 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$0.87

0.04 (4.82%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
Alliance MMA, FloSports announce event rights fee deal »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$77.45

-1.1 (-1.40%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Recommendations
Trinseo analyst commentary  »

Trinseo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$244.74

0.27 (0.11%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Hot Stocks
3M submits 510(k) application for Attest 24-minute readout »

3M announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

LXFT

Luxoft

$55.35

-1.8 (-3.15%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Upgrade
Luxoft rating change  »

Luxoft upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DST

DST Systems

$83.63

0.12 (0.14%)

, SSNC

SS&C

$48.48

-0.99 (-2.00%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Downgrade
DST Systems, SS&C rating change  »

DST Systems downgraded to…

DST

DST Systems

$83.63

0.12 (0.14%)

SSNC

SS&C

$48.48

-0.99 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$17.16

-0.6 (-3.38%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Options
GameStop put buyer realizes 26% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$119.72

0.02 (0.02%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Recommendations
Monsanto analyst commentary  »

Monsanto price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

08:00
01/17/18
01/17
08:00
01/17/18
08:00
General news
U.S. chain store sales fell 1.9% to 115.3 in the week ended January 13 »

U.S. chain store sales…

COG

Cabot Oil & Gas

$28.03

-0.85 (-2.94%)

07:59
01/17/18
01/17
07:59
01/17/18
07:59
Downgrade
Cabot Oil & Gas rating change  »

Cabot Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$110.40

-3.54 (-3.11%)

07:58
01/17/18
01/17
07:58
01/17/18
07:58
Recommendations
Westlake Chemical analyst commentary  »

Westlake Chemical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LADR

Ladder Capital

$14.62

1.03 (7.58%)

07:58
01/17/18
01/17
07:58
01/17/18
07:58
Hot Stocks
Ladder Capital reports unsolicited $15 per share takeover proposal from Related »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

LYB

LyondellBasell

$115.89

-1.79 (-1.52%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Recommendations
LyondellBasell analyst commentary  »

LyondellBasell price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$163.35

-7.35 (-4.31%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Technical Analysis
Technical Take: bluebird bio sharply higher in early trading »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AEP

American Electric

$67.50

0.04 (0.06%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

07:56
01/17/18
01/17
07:56
01/17/18
07:56
Periodicals
iPhone supply chain prepares for low order visibility in 1Q18, DigiTimes says »

Component suppliers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

UNH

UnitedHealth

$232.90

4.26 (1.86%)

07:56
01/17/18
01/17
07:56
01/17/18
07:56
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$109.67

-1.67 (-1.50%)

07:55
01/17/18
01/17
07:55
01/17/18
07:55
Recommendations
Celanese analyst commentary  »

Celanese price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

07:55
01/17/18
01/17
07:55
01/17/18
07:55
General news
Fedspeak resumes along with a Senate vote on Powell »

Fedspeak resumes along…

CLR

Continental Resources

$56.93

-0.73 (-1.27%)

07:54
01/17/18
01/17
07:54
01/17/18
07:54
Downgrade
Continental Resources rating change  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.